Balance Sheet Pola Pharma Inc.

As of March 31, 2019

| Assets | | | |
|----------------------------------|---------------|--|--|
| Current Assets | | | |
| Cash and Deposits | 1,110,101,121 | | |
| Trade Receivable | 4,004,097,018 | | |
| Inventories | 2,025,652,355 | | |
| Inter-Company Loan | 1,600,000,000 | | |
| Other Short-term assets | 263,667,544 | | |
| Total Current Assets | 9,003,518,038 | | |
| Non-Current Assets | | | |
| Property and Equipment | | | |
| Buildings | | | |
| Leasehold Improvement | 4,792,592 | | |
| Machinery & Equipment | 0 | | |
| Office Equipment | 13,810,774 | | |
| Accumulated impairment | (18,603,366) | | |
| Total Property and Equipment | 0 | | |
| Stock investment in Subsidiaries | 765,915,851 | | |
| Other Assets | 124,369,913 | | |
| Total Non-Current Assets | 890,285,764 | | |
| Total Assets | 9,893,803,802 | | |
| Liabilities | | | |
| Current Liabilities | | | |
| Trade Payable | 1,266,526,606 | | |
| Non-Trade Accounts Payable | 597,568,625 | | |
| Provision for Income tax | 17,182,657 | | |
| Other Liabilities | 499,783,110 | | |
| Total Current Liabilities | 2,381,060,998 | | |
| Non-Current Liabilities | | | |
| Advance received | 1,300,000,000 | | |
| Total Non-Current Liabilities | 1,300,000,000 | | |
| Total Liability | 3,681,060,998 | | |
| Equity | | | |
| Equity | | | |
| Share Capital | 100,000,000 | | |
| Capital Reserve | 6,432,019,108 | | |
| Deficits | (319,276,304) | | |
| Total Equity | 6,212,742,804 | | |
| Total Liabilities and Equity | 9,893,803,802 | | |

(JPY)

Income Statements

Pola Pharma Inc.

From January 1, 2019 To March 31, 2019

| | | (JPY) |
|---|-------------|---------------|
| Product Sales | | 2,349,561,097 |
| Cost of Sales | | 1,682,848,424 |
| Gross Profit | | 666,712,673 |
| Selling, General and Administrative Expenses | | |
| Personnel Expenses | | 518,872,949 |
| Research and Development | | 26,951,414 |
| Other Operating Expenses | | 526,135,208 |
| Total Selling, General and Administrative Expenses | | 1,071,959,571 |
| Operating Loss | | (405,246,898) |
| Non-Operating Income | | |
| Interest Income | 810,967 | |
| Miscellaneous Income | 621,616 | |
| Total Non-Operating Income | | 1,432,583 |
| Ordinary Loss | | (403,814,315) |
| Extraordinary Gain | 300,000,000 | |
| Extraordinary Gain | | 300,000,000 |
| Loss before Income Tax | | (103,814,315) |
| Income Tax | | 17,375,857 |
| Net Loss | | (121,190,172) |
| | | |

Statements of Shareholders' Equity

Pola Pharma Inc.

From January 1, 2019 To March 31, 2019

| | | | | <jpy></jpy> |
|--|---------------|-----------------|-------------------|---------------|
| | Share Capital | Capital Reserve | Retained Earrings | Total |
| | | | | Snarenoiders |
| Balance at December 31st, 2018 | 100,000,000 | 6,432,019,108 | (198,086,132) | 6,333,932,976 |
| Changes of items during the period | | | | |
| Net Income (Loss) | | | (121,190,172) | (121,190,172) |
| Total changes of items during the period | 0 | 0 | (121,190,172) | (121,190,172) |
| Balance at March 31st, 2019 | 100,000,000 | 6,432,019,108 | (319,276,304) | 6,212,742,804 |